arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Acurx Pharmaceuticals, Inc.

ACXP
$0.95 ▼ -0.08 (-8.20%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
26 Visible periods
17 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Acurx Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.0M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -22.4% ↘
FCF / Share $-0.40 ↗
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-1.68M
↑ +21.8% —
FCF / Share Free cash flow per share
$-0.40
↑ +22.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
5
Cash Quality ↑
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 6 years · 26 quarters